BIONET Corp. (TPEX:1784)
79.50
-1.50 (-1.85%)
At close: Mar 27, 2026
BIONET Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,237 | 1,222 | 1,127 | 980.38 | 921.42 | |
Revenue Growth (YoY) | 1.19% | 8.40% | 14.99% | 6.40% | 14.24% |
Cost of Revenue | 552.72 | 536.26 | 489.03 | 438.16 | 418.35 |
Gross Profit | 683.87 | 685.77 | 638.28 | 542.22 | 503.07 |
Selling, General & Admin | 545.2 | 483.75 | 433.23 | 391.95 | 385.97 |
Research & Development | 150.78 | 139.02 | 118.75 | 90.3 | 85.57 |
Operating Expenses | 698.34 | 623.37 | 553.58 | 485.39 | 471.86 |
Operating Income | -14.47 | 62.4 | 84.69 | 56.83 | 31.21 |
Interest Expense | -1.5 | -1.28 | -0.41 | -0.46 | -0.39 |
Interest & Investment Income | 26.24 | 24.91 | 15.03 | 8.96 | 7.37 |
Currency Exchange Gain (Loss) | - | 6.18 | -0.42 | 6.29 | -2.6 |
Other Non Operating Income (Expenses) | 9.01 | 7.31 | 5.56 | 4.18 | 5.41 |
EBT Excluding Unusual Items | 19.28 | 99.52 | 104.46 | 75.8 | 41.01 |
Gain (Loss) on Sale of Investments | - | 2.33 | 2.63 | -5.35 | 0.21 |
Gain (Loss) on Sale of Assets | - | 0.39 | 0 | 0.01 | -0.03 |
Pretax Income | 19.28 | 102.24 | 107.08 | 70.46 | 41.19 |
Income Tax Expense | 18.43 | 32.38 | 25.69 | 16.87 | 8.55 |
Earnings From Continuing Operations | 0.85 | 69.87 | 81.4 | 53.59 | 32.64 |
Minority Interest in Earnings | 50.58 | 13.84 | -3 | -15.62 | -6.02 |
Net Income | 51.43 | 83.7 | 78.4 | 37.97 | 26.62 |
Net Income to Common | 51.43 | 83.7 | 78.4 | 37.97 | 26.62 |
Net Income Growth | -38.56% | 6.76% | 106.47% | 42.62% | 108.96% |
Shares Outstanding (Basic) | 50 | 51 | 50 | 51 | 51 |
Shares Outstanding (Diluted) | 50 | 51 | 51 | 51 | 51 |
Shares Change (YoY) | -0.83% | 0.33% | -0.16% | -0.53% | 0.14% |
EPS (Basic) | 1.02 | 1.65 | 1.55 | 0.75 | 0.52 |
EPS (Diluted) | 1.02 | 1.65 | 1.55 | 0.75 | 0.52 |
EPS Growth | -38.18% | 6.45% | 107.50% | 42.86% | 108.83% |
Free Cash Flow | 24.42 | 75.15 | 133.05 | 65.78 | 3.71 |
Free Cash Flow Per Share | 0.48 | 1.48 | 2.63 | 1.30 | 0.07 |
Dividend Per Share | - | 1.416 | 0.663 | 0.654 | 0.448 |
Dividend Growth | - | 113.62% | 1.44% | 45.83% | 166.63% |
Gross Margin | 55.30% | 56.12% | 56.62% | 55.31% | 54.60% |
Operating Margin | -1.17% | 5.11% | 7.51% | 5.80% | 3.39% |
Profit Margin | 4.16% | 6.85% | 6.96% | 3.87% | 2.89% |
Free Cash Flow Margin | 1.98% | 6.15% | 11.80% | 6.71% | 0.40% |
EBITDA | 47.87 | 89.71 | 109.06 | 83.41 | 55.17 |
EBITDA Margin | 3.87% | 7.34% | 9.68% | 8.51% | 5.99% |
D&A For EBITDA | 62.33 | 27.31 | 24.37 | 26.59 | 23.96 |
EBIT | -14.47 | 62.4 | 84.69 | 56.83 | 31.21 |
EBIT Margin | -1.17% | 5.11% | 7.51% | 5.80% | 3.39% |
Effective Tax Rate | 95.60% | 31.67% | 23.99% | 23.94% | 20.75% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.